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F1 hybrid New Zealand Black (NZB) x New Zealand White (NZW) (NZB/NZW) mice spontaneously
develop an autoimmune disease analogous to systemic lupus erythematosus (SLE). Testosterone
exerts a powerful suppressive effect on this disorder in adult NZB/NZW mice. A series of experi-
ments was designed to determine if disease would also be suppressed by exposing fetal
NZB/NZW mice to increased testosterone. A model was developed in which NZB dams carrying
NZB/NZW fetuses were treated with testosterone in a dose adequate to masculinize the external
genitalia in female fetuses. NZB/NZW mice that were derived from testosterone-treated dams and
control NZB/NZW offspring were followed in a longevity study and had serial assays to assess
development of SLE. Additional experiments were carried out to measure lymphocyte subsets
and responses to mitogens. Results were compared with F1 hybrid offspring of C57BL/6 dams
crossed with DBA/2 males, which are not autoimmune and do not develop SLE. Spleen cells from
these groups were tested for Thy 1.2, CD4, CD8, and IgM receptors, and for responses to the
mitogens Concanavalin A (ConA) and lipopolysaccharide. Control male NZB/NZW fetuses had
unexpectedly high serum estradiol, which decreased significantly with maternal testosterone
treatment. The testosterone-exposed male NZB/NZW fetuses developed into adults that lived
longer than male NZB/NZW controls. Testosterone treatment of the dam was associated with ele-
vated terminal anti-DNA levels but did not alter markers of renal disease in adult NZB/NZW mice of
either sex. Testosterone-exposed NZB/NZW females had altered T-lymphocyte subsets and
testosterone-exposed males had increased response to ConA compared to controls. In male
NZB/NZW fetuses whose mothers were administered testosterone, the naturally high level of cir-
culating estradiol observed in untreated male fetuses was decreased significantly. This decrease
was associated with an increase in longevity. This unique observation has important implications
for fetal exposure to endocrine disruptors in the environment. Environ Health Perspect
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Introduction
Systemic lupus erythematosus (SLE) is a The predilection of SLE for women of
chronic and incurable disease charac- reproductive age (1), association between
terized by formation of autoantibodies disease flares and pregnancy (2), aberrant
and immune-mediated damage to key pattern of estrogen metabolism (3),
target organs such as the kidney (1). and relatively low levels of circulating
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testosterone in active disease (4) point
to an important role of reproductive
hormones in modulating SLE.
Matings between New Zealand Black
(NZB) and New Zealand White (NZW)
mice produce F1 NZB/NZW hybrids,
which develop a disease analogous to SLE.
These animals produce antibodies directed
against double-stranded DNA (anti-DNA)
and die prematurely with glomerulonephri-
tis and renal failure (5). Sex hormones are
important modifying factors in the disease
of NZB/NZW mice. Female NZB/NZW
mice have early-onset disease and accelerat-
ed mortality, with mean longevity of 40
weeks (6), and autoantibody formation is
accelerated by treatment with exogenous
17,3-estradiol (7).
In contrast, androgens are beneficial in
NZB/NZW mice. Males are expected to
live longer than the females. The mean age
of death in male NZB/NZW mice is 64
weeks (6), but early death occurs if male
mice are castrated before puberty (7).
Treatment with exogenous testosterone
improves survival in male castrates (7).
Testosterone therapy also improves survival
in NZB/NZW females that are treated
before or after the onset of renal disease,
and ovariectomy is not necessary for female
mice to receive therapeutic benefit (8,9).
Although testosterone modulates the
severity of autoimmune disease in NZB/
NZW mice, the critical periods at which
key interactions occur between endogenous
androgens and the immune system have
not been completely defined. It seems logi-
cal to assume that the protective effects of
naturally secreted androgens are exerted in
the postpubertal period in males, when
serum testosterone is found in high con-
centrations. Experimental evidence has
shown, however, that early exposure to
testosterone also has an important role in
modifying the course ofSLE in NZB/NZW
males. Castration leads to acceleration of
disease in male NZB/NZW mice if the
surgery is performed at 2 weeks ofage, but
postpubertal castration is relatively ineffec-
tive (8,10). A recent report from this labo-
ratory (11) showed that NZB/NZW males
had little androgen receptor-mediated
protection from severe disease between the
ages of6 weeks and 1 year.
Colborn et al. (12) have reviewed evi-
dence that maternal exposure to endocrine-
disrupting chemicals in the environment
can permanently alter the functioning of
developing systems, such as the immune
system, in offspring due to transport of
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chemicals from the mother during fetal life
and lactation. A number of endocrine-
disrupting chemicals typically encountered
in water, air, and food and commonly
found in human tissue are capable of per-
manently disrupting developing systems by
binding to receptors for estrogen and
androgen, which regulate the differentia-
tion of many tissues; endocrine disruptors
can either mimic or antagonize the actions
of natural sex steroids (13-15). Thus,
findings concerning the role of estrogen
and androgen in the etiology of autoim-
mune disease are relevant to our under-
standing ofthe potential impact that expo-
sure to endocrine disruptors during devel-
opment can have on this disease.
This paper is the third in a series of
publications that report the effects of hor-
monal manipulations on the developing
immune system of NZB/NZW mice dur-
ing prenatal life (16,17). A model was cre-
ated in which NZB dams, pregnant with
NZB/NZW fetuses, were treated in late
pregnancy with testosterone or with the
androgen blocker, flutamide. Both mater-
nal treatments failed to produce long-last-
ing influences on female offspring, but the
treatments were associated with increased
longevity in the NZB/NZW males (16).
This paper focuses on gestational
testosterone therapy in NZB dams and the
influences of this treatment on their
NZB/NZW offspring. Although maternal
exposure to exogenous testosterone did not
affect the lifespan in the NZB/NZW
females produced by the treated dams,
maternal testosterone treatment was associ-
ated with an unusual effect in the males.
Unexpectedly, NZB/NZW males from
androgen-implanted mothers had pro-
longed survival and lived significantly
longer than comparable control males from
untreated NZB dams (Figure 1) (16).
The hormonal status of the male
NZB/NZW fetuses was unique. At the ges-
tational age of 18 days, control males had
very high serum estradiol that exceeded
concentrations in littermate females by a
factor of 2.6. Maternal treatment with
testosterone significantly reduced (by one-
third) serum estradiol concentrations in the
male fetuses (Table 1) (17). Testosterone-
treated NZB dams had significantly elevat-
ed serum testosterone (data not shown),
but maternal treatment did-not alter fetal
serum testosterone levels (Table 1) (17).
We now describe serial assessments
of disease progression, lymphocyte sub-
sets, and responses to T-lymphocyte
and B-lymphocyte mitogens in adult
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Figure 1. Survival in female and male NZB/NZW mice. Female mice and male mice were delivered by cesarean
section from NZB dams that had been treated from days 13-18 of pregnancy with implanted testosterone, 0.75
mg. Control NZB/NZW females and males were delivered by cesarean section from sham-treated NZB dams. The
mean age at death in female offspring of testosterone-treated dams did not differ significantly from offspring of
control dams. Mean longevity in males from the dams treated with testosterone was prolonged (61 weeks±4)
compared to males from control dams (48±2); p<0.001. Figure 1 is adapted from Keisler et al. (16) and is used
with permission ofthe publisher.
Table 1. Serum estradiol and testosterone concentrations in NZB/NZWfetuses.a
Sex of offspring Maternal treatment Estradiol (pg/ml) Testosterone (pg/ml)
Female Testosterone 137 ± 44 2988 ± 408
Sham 125 ±44 1585 ± 762
Male Testosterone 205* ± 42 1958 ± 485
Sham 327 ±42 2706±829
"Offspring were delivered by cesarean section from NZB dams that received either subcutaneous implants con-
taining testosterone or sham treatment. Values are expressed as mean ± 1 SEM. *p < 0.05 for male fetuses from
testosterone-treated dams versus male fetuses from sham-treated dams. Data modified from Keisler et al. (17)
and used with permission ofthe publisher.
NZB/NZW offspring of hormonally
manipulated dams.
Materials and Methods
Animal
Autoimmune (SLE) Mice. New Zealand
Black (NZB) females and New Zealand
White (NZW) males Uackson Laboratories,
Bar Harbor, ME) were paired to produce
NZB/NZWoffspring.
Nonautoimmune Mice. C57BL/6
females and DBA/2 males (Harlan Sprague
Dawley, Indianapolis, IN) were paired to
produce C57BL x DBA/2 (C57/DBA2)
offspring. Animals were purchased at
5 weeks ofage and maintainedwith an auto-
matic 12-hr on, 12-hr offlight cycle in the
Research Service of the Harry S. Truman
Memorial Veterans' Hospital under condi-
tions described in an earlier publication
(17). At 6 weeks ofage, NZB females were
paired with NZW males, and C57BL/6
females were paired with DBA/2 males.
Females were checked dailyforvaginal plugs,
and the appearance ofaplugwas day0.
TestosteroneTreatment
Implants were made of 1-cm lengths
(between the plugged ends) ofSilastic tubing
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(0.06-inch inner diameter, 0.125-inch
outer diameter; Dow Corning, Midland,
MI) filled with 0.75 mg testosterone
(Sigma Chemical Co., St. Louis, MO) in
0.02 ml sesame oil. Fifteen NZB dams and
eight C57BL/6 dams were anesthetized
with Metofane (methoxyflurane) (Pitman-
Moore, Inc., Mundelein, IL) and implanted
on day 13 ofpregnancy (16). The 0.75-mg
dose of testosterone was chosen because it
was determined in preliminary experiments
that this was the lowest dose that signifi-
cantly masculinized the external genitalia of
female offspring. Masculinization was
defined on the basis ofincreased anogenital
space (the length between the anus and the
genital papilla that becomes the scrotum in
males). The dose was, however, low enough
so that defeminization offemale fetuses did
not occur (i.e., these animals retained the
capacity to ovulate) (16).
The vagina ofthe female mouse is usu-
ally open by 4 weeks of age, but it was
anticipated that opening would be altered
by prenatal exposure to exogenous testos-
terone (18). Vaginal opening did not occur
in female F1 offspring oftestosterone-treat-
ed NZB and C57BL/6 dams by 12 weeks
of age, and all of these offspring had hys-
terectomies (16) to prevent endometritis
that would have occurred because of lack
of uterine drainage. Ovaries were carefully
left intact. This surgery did not cause
expression of disease to differ, and data
from these mice were pooled with data
from other female NZB/NZW offspring of
sham-treated dams (16).
ShamTreatment
Twelve NZB dams and 5 C57BL/6 dams
received implants containing 0.02 ml
sesame oil on day 13 of gestation, and 8
NZB dams and 4 C57BL/6 dams received
injections of sesame oil-alcohol vehicle on
days 13, 14, 15, 16, 17, and 18 of gesta-
tion. Offspring ofdams that received either
sham treatment had similar anogenital
spaces and comparable expression of
disease, and the results were combined.
Derivation ofOffipring
Pups were delivered from all dams by
cesarean section on day 18 ofgestation, fos-
tered to post-partum CF-1 mothers from
the outbred colony of F. vom Saal, and
weaned 21 days after birth (16).
LongevityStudy
ofNZB/NZWOff'ring
A longevity study was performed to deter-
mine ifNZB dams exposed to testosterone
in the last third of pregnancy produced
NZB/NZW offspring with altered expres-
sion ofautoimmune disease. The following
groups ofNZB/NZW offspring were stud-
ied: female (n=24) and male (n=22) off-
spring of testosterone-treated dams and
control female (n= 34) and male (n=29)
offspring ofsham-treated dams.
AssessmentofActive
AutoimmuneDisease
Mice were bled from the orbital plexus and
urine was collected at 12, 24, 36, and 48
weeks ofage. Mice were examined daily for
signs of disease. They were bled, checked
for albuminuria, sacrificed, and necropsied
according to the protocol described in
earlier publications when they developed
neoplasms or appeared moribund (19-21).
Binding of heat-inactivated mouse
serum to 14C-labeled DNA derived from
Escherichia coli (Amersham Corporation,
Arlington Heights, IL) was measured in a
modified Farr assay. Values greater than
20% binding indicated the presence ofanti-
DNA (22,23). Urine was tested for albu-
minuria with Albustix (Ames Co., Elkhart,
IN) and graded on a scale of0 to 4+ accord-
ing to five colors on a chart provided by the
manufacturer. Results were classified as 0,
1+ (30 mg/dl), 2+ (100 mg/dl), 3+ (300
mg/dl), or 4+ (>2000 mg/dl). Albuminuria
greater than 2+ was considered significant.
Blood urea nitrogen (BUN) was assayed
using a colorimetric assay kit (American
Monitor Corp., Indianapolis, IN). In this
laboratory, the mean BUN level in stored
frozen sera was 30 mg/dl ±4 SEM for nor-
mal female mice and 35 mg/dl ± for normal
male mice (24).
LymphocyteEnumerationand
MitogenicResponses
Groups of mice, each group containing 5
NZB/NZW hybrids and 5 C57/DBA2
hybrids ofeach sex from testosterone-treat-
ed or control dams, were studied at 8
weeks and 16 weeks ofage. These animals
were not included in the longevity study.
MonoclonalAntibodies andAndsera
Biotin-conjugated anti-Thy 1.2, phycoery-
thrin (PE)-conjugated anti-L3T4 (CD4),
fluorescein isothiocyanate (FITC)-conju-
gated anti-Lyt 2 (CD8), and PE-conjugated
streptavidin were purchased from Becton
Dickinson (Mountain View, CA). Other
reagents were FITC-conjugated affinity
purified F(ab')2 sheep anti-mouse IgG
(Cooper Biomedical, Inc., Malvern, PA),
and biotinylated F(ab')2 fragment rabbit
anti-mouse IgM (Zymed Laboratories,
South San Francisco, CA).
Preparation ofCells
Single cell suspensions were prepared by
mechanically dissociating spleens in RPMI
1640 (Gibco, Grand Island, NY). The
cells were filtered through nylon mesh and
washed with RPMI 1640 enriched with
0.5% fetal calf serum (FCS) (Gibco),
L-glutamine, penicillin, and streptomycin.
Lymphocytes were isolated on a density
gradient (Ficoll-Paque, Pharmacia,
Piscataway, NJ). Cells were diluted to
1 x 106/ml, and 0.1-ml aliquots were added
to 12X75-mm plastic test tubes and
washed in phosphate-buffered saline (PBS).
Cells were stained with monoclonal anti-
bodies at saturating concentrations
(0.2-5 pg) at 40C for 30 min. PE-strepta-
vidin was added to tubes containing
biotinylated antibodies. After staining was
complete, cells were washed twice with
PBS containing FCS, washed a third time
with PBS without FCS, fixed in 0.1 ml
0.5% paraformaldehyde, and examined
16 hr later by flow cytometric analysis.
A FACScan flow cytometer (Becton
Dickinson) was used under standardized
conditions for measurement of light scat-
ter and fluorescence (25). Fluorescence
signals were collected at 5 1 5 ± 10 nM
(FITC) and 600 ± 15 nM (PE) in single-
or dual-parameter histogram format from
10,000 cells with the lymphocyte light
scatter gates, as defined by forward and
perpendicular light scatter signals. Data
were expressed as the percentage of cells
bearing the antigen ofinterest. When nec-
essary, nonspecific staining was subtracted
from positive cells.
LymphocyteTransformation
Mitogenic responses of splenocytes to
Concanavalin A (ConA) (Pharmacia),
0.5 jig, or lipopolysaccharide (LPS) (E. coli
026:B6; Difco, Detroit, MI), 40 pg, were
assayed by incubating the cells with either
ConA or LPS to stimulate cell division,
pulsing the dividing cells with 3H-thymi-
dine, harvesting the cells on glass fiber filter
paper, and using recovered CPM as a mea-
sure of cell proliferation. This assay was
performed as described in an earlier publi-
cation (24), except that phenol red-free
RPMI 1640 media (Gibco, Grand Island,
NY) was used. Mean values of triplicate
samples were determined, and results were
expressed as differences in counts per
minute (ACPM) between stimulated and
unstimulated cultures.
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StatisticalAnalyses
Analysis of variance procedures and mean
comparison tests were used to determine
differences in dependent variables in each
experiment (General Linear Models, SAS
Institutes, Cary, NC). Planned compar-
isons were made using least significant
difference procedures (26).
Results
Longevity Study
ofNZB/NZWOffsprng
Testosterone treatment of NZB dams in
the last third ofgestation affected longevity
of the offspring in a sex-dependent man-
ner. Figure 1 illustrates cumulative survival
in NZB/NZW females and males that were
delivered from testosterone-treated or
sham-treated control dams. The major
cause of death in mice of both sexes was
SLE, manifested as renal disease leading to
renal failure and vasculitis (16). Age at
death in female offspring of testosterone-
treated dams was 34± 1 week; longevity in
this group did not differ from female off-
spring of control dams (37 ±2 weeks). In
contrast, outcome in NZB/NZW males
was affected by the maternal testosterone
therapy. Males from testosterone-treated
dams had lifespans of 61 ±4 weeks versus
male offspring of control dams (48 ±2
weeks; p<0.001) (16).
AssessmentofActive
Autoi'mune Disease
Serial assays of anti-DNA, an important
marker of disease activity in NZB/NZW
mice (27), are shown in Table 2. All
female offspring had the expected age-
dependent increase in anti-DNA concen-
tration. In females produced by the testos-
terone-treated NZB dams, anti-DNA
appeared to exceed control values at 36
weeks of age; this increase was significant
in serum that was collected at spontaneous
death. Anti-DNA concentrations in male
offspring also increased with age and were
not altered by testosterone treatment of
the dam.
Progression of kidney disease was not
changed by perinatal exposure to testos-
terone in mice ofeither sex. Table 3 illus-
trates albuminuria, which appeared in
female and male mice by 24 weeks ofage.
Albuminuria was not accelerated in off-
spring of testosterone-treated dams.
Terminal increases in BUN concentrations
reflected the development of renal failure
at the time of spontaneous death in
NZB/NZW mice ofboth sexes (Table 3).
Table 2. Anti-DNA in NZB/NZW mice.a
Anti-DNA (% binding)
Age (weeks)
Sex of offspring Maternal treatment 12 24 36 48 Terminal
Females Testosterone 8 ± 1 11 ± 2 61 ± 7 ND 60 ± 6*
Sham 10±2 11±2 49± 10 ND 45±5
Male Testosterone 9± 1 10 ±2 28± 5 45 ± 5 42 ±9
Sham 12±1 9±2 30±5 46±8 26±6
ND, not determined. aAntibodies to ds-DNA are expressed as percent 14C-DNA bound to mouse serum. Values
greater than 20% are abnormal. Results are expressed as mean ± 1 SEM. *p < 0.05 for DNA binding in terminal
serum from female offspring oftestosterone-treated dams versus female offspring of sham-treated dams.
Table 3. Parameters of renal disease in NZB/NZW mice.a
Albuminuria
Age (weeks)
Sex of offspring Maternal treatment 12 24 36 48 Terminal
Female Testosterone 0 23 70 NDa 76
Sham 0 17 40 ND 88
Male Testosterone 0 4 0 35 56
Sham 0 0 20 43 65
BUN
Female Testosterone 23± 1 29 ±2 36 ±4 ND 154± 17
Sham 22±1 26±2 27±6 ND 138±14
Male Testosterone 23 ±2 22 ± 2 20 D 3 30 D 7 127 ± 13
Sham 27±1 22±2 30±3 47±10 83±16
ND, not determined. aAlbuminuria is shown as percent of surviving mice with 3+ to 4+ readings on Albustix. BUN
results are milligram per decaliter and expressed as mean ± 1 SEM. Only one female mouse was alive at the age
of 48 weeks.
LymphocytePopulations
inNZB/NZWMice
Table 4 displays percentages of cells with
surface markers for T lymphocytes (Thy 1.2,
CD4, and CD8) and B lymphocytes (IgM).
At 8 weeks ofage, female NZB/NZW mice
from testosterone-treated dams had a lower
percentage ofsplenocytes expressing Thy 1.2
compared to NZB/NZW females from
sham-treated dams (18 vs 24%; p<O.01).
Treating NZB dams with testosterone was
associated with similar reduction in the
proportion of CD4+ cells in female off-
spring (p<0.05). No significant differences
were found between percentages of cells
bearing CD8 or IgM in offspring of dams
that received testosterone or sham treat-
ment. Data from 16-week-old mice are not
shown; at this point, NZB/NZW offspring
from treated or sham-treated dams did not
differ with respect to T-lymphocyte or B-
lymphocyte markers.
Lymphocyte Populations
inC57/DBA2 Mice
Percentages of spleen cells from 8-week-
old C57/DBA2 mice that reacted with the
four antibodies of interest are in Table 4.
Testosterone treatment of C57BL/6 dams
did not appear to affect proportions of
cells bearing each marker. Likewise, off-
spring from treated and control dams,
studied at 16 weeks of age, did not differ
with respect to cell surface antigens (data
not shown).
Mitogenic Responses
inNZB/NZWMice
Proliferation of NZB/NZW spleen cells
in response to the T-lymphocyte mito-
gen, ConA, and the B-lymphocyte mito-
gen, LPS, are shown in Table 5. At 8
weeks of age, there was a trend for
increased 3H-thymidine uptake in
response to both mitogens in female and
male offspring of testosterone-treated
dams. This increase was significant only
for ConA-cultured spleen cells from
the testosterone-exposed NZB/NZW
males, compared to male offspring of
sham-treated dams (p<0.05). ConA and
LPS produced equivalent responses in
NZB/NZW mice of both sexes, at 8 and
16 weeks ofage.
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Table 4. Cell surface antigens on spleen cells from 8-week-old NZB/NZW and C57/DBA2 mice.a
% Positive cells
F1 Hybrid Sex of offspring Maternal treatment Thy 1.2 CD4 CD8 IgM
NZB/NZW Female Testosterone 18 ± 2* 16 ± 1** 7 ± 0.5 60 ± 3
Sham 24±2 18±1 7±0.5 61±3
Male Testosterone 23 ±2 17± 1 6± 0.5 58 ±3
Sham 22±2 16±1 7±0.6 50±4
C57/DBA2 Female Testosterone 18 ± 5 13 ± 1 6 ± 1 70 ± 3
Sham 17±5 13±1 6±1 70±3
Male Testosterone 16 ±5 13* ± 1 6± 1 69±3
Sham 27±5 12±1 5±1 68±3
"Percentages of spleen cells with positive staining for each antigen are expressed as mean ± 1 SEM. *p< 0.01 and
**p < 0.05 for female NZB/NZW offspring of testosterone-treated dams versus female NZB/NZW offspring of
sham-treated dams.
Table 5. Responses to mitogenic stimulation with ConA and LPS in 8-week-old and 16-week-old NZB/NZW and
C57/DBA2 micea
8 weeks 16 weeks
F1 Hybrid Sex ofoffspring Maternal treatment ConA lPS ConA LPS
NZB/NZW Female Testosterone 105 ± 7 45 ± 4 68 ± 4 31 ± 2
Sham 89±11 33±6 66±1 32±3
Male Testosterone 97 ± 10* 41 ± 7 67 ± 4 36 ± 2
Sham 77±13 27±6 68±4 33±3
C57/DBA2 Female Testosterone 57 ± 19 30 ± 7 41 ± 18 30 ± 4
Sham 59±17 46±3 53±15 36±8
Male Testosterone 35± 16 47 ±3 54± 15 34±6
Sham 36±16 43±4 52±16 37±5
8CPM x 103. Incorporation of 3H-thymidine by dividing cells is expressed as mean ± 1 SEM of A CPM (CPM in
stimulated culture - CPM in unstimulated culture). *p<0.05 for female offspring of testosterone-treated dams
versus female offspring of sham-treated dams.
Mitogenic Responses
in C57/DBA2 Mice
In nonautoimmune C57/DBA2 hybrids,
active responses were observed when spleen
cells were cultured with either mitogen.
Response were not influenced by prenatal
treatment, sex, or age (Table 5).
Discussion
Gonadal hormones mediate severity of
autoimmune disease in NZB/NZW mice,
but the mechanisms and timing ofthe most
important interactions with the immune
system have not previously been defined.
Estrogens are capable ofsuppressing natur-
al killer cell cytotoxic activity (28) and
stimulating intense B-cell activity (28,29)
in NZB/NZW mice. Androgenic hor-
mones exert widespread influences on cell-
mediated immunity, sustaining interleukin
(IL)-2 production (30) and increasing
T-cell activity in castrated males (31).
It may be reasoned that hormones
exert modulating effects within the
developing immune system of the fetus,
whereas other important influences occur
when concentrations of hormones change
at puberty or after the animal has reached
sexual maturity. We have investigated hor-
monal interactions in the last third ofges-
tation, a period in which gonadal steroids
regulate the differentiation of numerous
organ systems.
Several unique models have been devel-
oped in this laboratory to facilitate studies
ofaltered prenatal hormone concentrations
on the subsequent course of autoimmune
disease in NZB/NZW mice. In the testos-
terone implant model, pregnant NZB dams
are treated on days 13 to 18 of gestation
with implanted testosterone in a dose that
somewhat masculinizes genitalia of the
female NZB/NZW offspring (16). This
treatment results in long-lived male NZB/
NZW fetuses that survive for a significantly
longer period compared to NZB/NZW
males from control dams (16).
This present paper presents mea-
surements of three parameters of active
autoimmune disease in female and male
NZB/NZW offspring oftestosterone-treat-
ed and control dams. Anti-DNA, albumin-
uria, and BUN were assayed serially during
the first year of life. These indicators
increased as expected as the animals grew
older. At 36 weeks of age, female
NZB/NZW mice from testosterone-treated
dams had active production of anti-DNA
(mean =61%). Anti-DNA remained elevat-
ed in the terminal phase of SLE in this
group (60% vs 45% in females from sham-
treated dams; p<0.05). The increased anti-
DNA concentration, a marker of active
disease, was not associated with accelerated
mortality in the females from hormone-
treated dams.
This analysis suggested that prenatal
exposure to exogenous androgens was asso-
ciated with accelerated autoantibody for-
mation in the females. Paradoxically, their
lifespans were not shortened compared to
same-sex controls. In the corresponding
male littermates, testosterone-exposed off-
spring did survive longer than expected in
the face of active autoimmune disease and
renal insufficiency. Their increased lon-
gevity was compatible with the existence of
a protective factor or factors that prevented
early mortality in the face of active anti-
DNA formation. Death was delayed in
these males even though they had long-
standing, active disease that paralleled
males from sham-treated dams.
Our understanding of the protective
effects that the prenatal hormone milieu
may exert on longevity is confounded by
changes that occur as the mice become
adults. Females produce cyclic estrogen and
prolactin, which are immunostimulatory,
and males produce immune-suppressing
androgens. We are currently examining
mechanisms by which the prenatal hor-
monal environment could interact with
post-pubertal hormone surges in adult
NZB/NZW mice to prolong survival in
animals with active SLE.
Additional groups of NZB/NZW off-
spring of testosterone-treated and control
dams were tested for percentages of cells
bearing T-lymphocyte or B-lymphocyte
markers and for mitogenic responses to
ConA and LPS. Results were compared
with a genetically distinct F1 hybrid
(C57/DBA2) that does not develop auto-
immune disease. Of interest, 8-week-old
female NZB/NZW offspring of testos-
terone-treated dams had significant reduc-
tions in percentages ofspleen cells bearing
surface antigens that are characteristic ofT
lymphocytes (Thy 1.2), and the helper/
inducer T-lymphocyte subset (CD4). This
apparent reduction in T lymphocytes,
however, did not suppress responses to the
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T-lymphocyte mitogen, Con-A. The
difference in T-lymphocyte subsets did not
persist to 16 weeks of age, and was not
noted in NZB/NZW males or C57/DBA2
hybrids. Male NZB/NZW mice from treat-
ed dams had no changes in lymphocyte sub-
sets, but a significant increase in response to
ConAwas noted at 8 weeks ofage.
Maternal testosterone treatment did
have some longstanding effects on lym-
phoid cell subsets and responses to mito-
gens. In testosterone-exposed female
NZB/NZW offspring, the reduced num-
bers of CD4+ T-helper cells at 8 weeks of
age may have represented either a lag in
production, or increased destruction of a
key group oflymphocytes that is needed to
sustain autoimmune disease in NZB/NZW
mice (32). The relative paucity of CD4+
cells could have been protective, in that it
might have affected expression of disease
and resulted in some prolongation oflife in
this group of female mice with very high
anti-DNA levels. On the other hand, the
trend to increased responses to ConA and
LPS in females and the significant increase
in ConA responsiveness in males from
testosterone-treated dams argues for a
transient increase in activity of the
immune system at an early age. The signi-
ficance of this response is not clear; it
could reflect an altered production oflym-
phocyte growth factors that may or may
not be associated with the phenomenon of
increased longevity in testosterone-exposed
NZB/NZW males.
Our evaluations of the immune system
in these animals did not identify a single
protective factor that could have extended
longevity in testosterone-exposed NZB/
NZW mice. Future investigations will focus
on identifying changes in the prenatal and
postnatal hormonal environments that may
have affected the genesis oflymphocyte sub-
sets or reset these cells to produce immune
mediators that have protective as well as
immune-stimulating properties. Additional
studies are required to define lymphocyte
profiles and function in juvenile animals,
and to separate the effects of prenatal hor-
mone exposure from immunosuppressive
actions ofendogenous androgens.
In the course of investigating the
hormonal environment in which fetal
NZB/NZW mice develop, we discovered
that unmanipulated NZB/NZW males had
unprecedented elevation of serum estradiol
on day 18 of fetal life. For comparison,
the observed concentration of serum
estradiol in 18-day C57/DBA2 fetuses was
(mean ± SEM) 158 pg/ml ±48 for females
and 183 pg/ml±38 for males. Values for
CF-I mouse fetuses at 18 days ofgestation
were females, 113 pg/ml±7 and males, 90
pg/ml±4 (33). In the male NZB/NZW
fetuses, the concentration of estradiol,
(mean ± SEM) 327 pg/ml ± 42, greatly
exceeded that of the female NZB/NZW
littermates (125 pg/ml ± 44), p< 0.01.
Testosterone treatment of the NZB dams
decreased serum estradiol in male NZB/
NZW fetuses to (mean) 205 pg/mi (17).
The maternal treatment that decreased
fetal estradiol in the NZB/NZW males did
not alter their circulating testosterone, but
resulted in significant prolongation of life-
spans. These findings lead to the prediction
that increased concentrations of estradiol
during fetal life are related to early mortali-
ty from active autoimmune disease in
NZB/NZW males.
The findings that NZB/NZW male
fetuses have elevated serum estradiol com-
pared to concentrations in male fetuses in
nonautoimmune strains (16,17,34) and
that a decrease in serum estradiol during
fetal life in NZB/NZW males was associ-
ated with an increase in longevity, have
important implications for studies ofenvi-
ronmental influences on autoimmune
disease. Our findings suggest that environ-
mental endocrine disrupting chemicals
that can bind to estrogen receptors and
mimic the action of estradiol may affect
the fetus and alter the subsequent course
ofautoimmune disease.
Numerous chemicals present in food,
water, and air can bind to estrogen recep-
tors and are referred to as environmental
estrogens. Man-made environmental
chemicals with estrogenic activity include
pesticides, such as DDT and methoxy-
chlor, components of commonly used
products, such as plastics and soaps, and
the epoxy lining ofcans, such as octylphe-
nol, nonylphenol and bisphenol-A (14,15).
Environmental estrogens synthesized by
man differ from naturally occurring plant
estrogens (phytoestrogens) in that only
man-made chemicals persist while stored in
fat for prolonged periods after ingestion;
phytoestrogens are rapidly cleared from the
circulation (14). Thus, maternal exposure
to persistent environmental estrogens
before or during pregnancy and lactation
can result in exposure of offspring to the
chemicals during differentiation of critical
organ systems.
While it has been recognized for some
time that endogenous steroids modulate
immune function and are involved in sex
differences in immune function, relatively
little attention has been paid to the effects
ofexposure to steroids during critical peri-
ods in the organization of the developing
immune system on subsequent immune
function. Steroids exert organizational
effects on differentiating tissues, including
tissues in the immune system, such that the
functioning of the tissue throughout the
remainder of life is permanently altered
as a result of a change in hormone levels
during differentiation (35).
The possibility that exposure of fetuses
or newborns to endocrine-disrupting chem-
icals might be involved in a host ofdiseases
associated with disfunction in the immune
system needs to be examined. Information
concerning parental exposure to endocrine
disruptors can then be analyzed in relation
to diseases that do not become manifest
until the offspring are adults.
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